Anti-CD122 (shared IL-2 and IL-15 receptor β-chain) monoclonal antibody. Blocks trans presentation of IL-15 to T cells. In a phase I study in LGLL, the drug was safe but showed no clinical efficacy. This evidence concerns the gene IL2 and T-cell large granular lymphocyte leukemia.